APA (7th ed.) Citation

Matsumori, Y., Nagy, K., Takahashi, A., Tanaka, S., Takeshima, T., Forero, G., . . . Yamamoto, T. (2026). Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study. Neurology & Therapy, 15(3), 1137. https://doi.org/10.1007/s40120-026-00905-3

Chicago Style (17th ed.) Citation

Matsumori, Yasuhiko, et al. "Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study." Neurology & Therapy 15, no. 3 (2026): 1137. https://doi.org/10.1007/s40120-026-00905-3.

MLA (9th ed.) Citation

Matsumori, Yasuhiko, et al. "Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study." Neurology & Therapy, vol. 15, no. 3, 2026, p. 1137, https://doi.org/10.1007/s40120-026-00905-3.